High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients-Reference-Cited by-同舟云学术

High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients

Published:2021-06-07 Issue:7 Volume:34 Page:1293-1305
ISSN:0934-0874
Container-title:Transplant International
language:en
Short-container-title:Transpl Int

Author:

Nitta Hidetoshi¹,Younès Aline¹,El‐domiaty Nada¹²^ORCID,Karam Vincent¹,Sobesky Rodolphe¹,Vibert Eric¹,Coilly Audrey¹,Maria Antonini Teresa¹,De Martin Eleonora¹,Cherqui Daniel¹,Baba Hideo³,Rosmorduc Olivier¹,Adam René¹,Samuel Didier¹,Saliba Faouzi¹^ORCID

Affiliation:

1. AP‐HP Hôpital Paul Brousse Centre Hépato‐Biliaire Inserm UMR‐S 1193 Université Paris‐ Saclay Villejuif France

2. Tropical Medicine Department Faculty of Medicine Zagazig University Zagazig Egypt

3. Department of Gastroenterological Surgery Graduate School of Life Sciences Kumamoto University Kumamoto Japan

Publisher

Frontiers Media SA

Subject

Transplantation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tri.13897

Reference52 articles.

1. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report